Skip to main content

Advertisement

SpringerLink
Log in

Epidemiology of Chagas disease in Europe: many calculations, little knowledge

  • Review
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

Chagas disease and its causative agent Trypanosoma cruzi are endemic in almost all countries in South and Middle America. Currently, there are more than 10 million affected people. It is the most common reason for heart failure and a frequent cause of intestinal problems in Latin America. The phenotype of the Chagas cardiomyopathy is varying. Dilative cardiomyopathy, often accompanied by an apical aneurysm is the most common finding in the end stage heart failure, but rhythm disorders like conduction blocks, ventricular or supraventricular forms of tachycardia or repolarization changes occur as well, mainly in the early stages. Migration of infected people leads to a distribution from the endemic countries to North America and Europe. Although more than 500,000 people of Latin American origin are currently living in Europe, Chagas disease is not considered as a public health problem, yet. Cases of transmission via blood donation, organ transplantation or from mother-to-child are reported for several European countries but there is no database for Germany. Current epidemiological data are mostly available from regional surveys from other countries or are extrapolated. Hence, there is a large variation in the estimated numbers on the incidence of Chagas. Robust and reliable data are lacking. This review gives an overview on the currently available data and calls for a German Chagas surveillance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Adesse D, Azzam EM, Meirelles Mde N, Urbina JA, Garzoni LR (2011) Amiodarone inhibits Trypanosoma cruzi infection and promotes cardiac cell recovery with gap junction and cytoskeleton reassembly in vitro. Antimicrob Agents Chemother 55(1):203–210

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Alarcón de Noya B, Díaz-Bello Z, Colmenares C, Ruiz-Guevara R, Mauriello L, Zavala-Jaspe R, Suarez JA, Abate T, Naranjo L, Paiva M, Rivas L, Castro J, Márques J, Mendoza I, Acquatella H, Torres J, Noya O (2010) Large urban outbreak of orally acquired acute Chagas disease at a school in Caracas. Venezuela J Infect Dis 201(9):1308–1315

    Article  Google Scholar 

  3. Andrade JP, Marin Neto JA, Paola AA, Vilas-Boas F, Oliveira GM, Bacal F, Bocchi EA, Almeida DR, Fragata Filho AA, Moreira Mda C, Xavier SS, Oliveira Junior WA, Dias JC (2011) I Latin american guidelines for the diagnosis and treatment of Chagas’ heart disease: executive summary. Arq Bras Cardiol 96(6):434–442

    Article  PubMed  Google Scholar 

  4. Andrade ZA (1999) Immunopathology of Chagas disease. Mem Inst Oswaldo Cruz 94(Suppl 1):71–80

    Article  PubMed  Google Scholar 

  5. Añez N, Carrasco H, Parada H, Crisante G, Rojas A, Fuenmayor C, Gonzalez N, Percoco G, Borges R, Guevara P, Ramirez JL (1999) Myocardial parasite persistence in chronic chagasic patients. Am J Trop Med Hyg 60:726–732

    PubMed  Google Scholar 

  6. Angheben A, Anselmi M, Gobbi F, Marocco S, Monteiro G, Buonfrate D, Tais S,Talamo M, Zavarise G, Strohmeyer M, Bartalesi F, Mantella A, Di Tommaso M, Aiello KH, Veneruso G, Graziani G, Ferrari M, Spreafico I, Bonifacio E, Gaiera G,Lanzafame M, Mascarello M, Cancrini G, Albajar-Vinas P, Bisoffi Z, Bartoloni A. (2011) Chagas disease in Italy: breaking an epidemiological silence. Euro Surveill. 16(37):pii = 19969

    Google Scholar 

  7. Arrieta Gallastegui R, Cañavate Cañavate C, Castro Izaguirre E, Gascon Brustenga J, Madoz Resano P, Puente Puente S, Sauleda Oliveras S, Vesga Carasa MA, Moro Domingo E. (2009) Chagas disease and blood donation. Ministerio de sanidad y politica social (secretariat-general for health) Madrid

  8. Barona-Vilar C, Giménez-Martí MJ, Fraile T, González-Steinbauer C, Parada C, Gil-Brusola A, Bravo D, Gómez MD, Navarro D, Perez-Tamarit A, Fernandez-Silveira L, Fullana-Montoro A, Borrás R (2012) Prevalence of Trypanosoma cruzi infection in pregnant Latin American women and congenital transmission rate in a non-endemic area: the experience of the Valencian health programme (Spain). Epidemiol Infect 140(10):1896–1903

    Article  CAS  PubMed  Google Scholar 

  9. Barrett MP, Burchmore RJ, Stich A, Lazzari JO, Frasch AC, Cazzulo JJ, Krishna S (2003) The trypanosomiases. Lancet 362(9394):1469–1480

    Article  PubMed  Google Scholar 

  10. Bart A, Hodiamont CJ, Grobusch MP, van den Brink RB, Smout AJ, van Gool T (2011) De ziekte van Chagas in Nederland. Ned Tijdschr Geneeskd 155:A3170

    PubMed  Google Scholar 

  11. Basile L, Jansà JM, Carlier Y, Salamanca DD, Angheben A, Bartoloni A, Seixas J, Van Gool T, Cañavate C, Flores-Chávez M, Jackson Y, Chiodini PL, Albajar-Viñas P, Working Group on Chagas Disease. (2011) Chagas disease in European countries: the challenge of a surveillance system. Euro Surveill. 16(37):pii = 19968

    Google Scholar 

  12. Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, Dantas RO, Maguire JH, Acquatella H, Morillo C, Kirchhoff LV, Gilman RH, Reyes PA, Salvatella R, Moore AC (2007) Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 298(18):2171–2181

    Article  CAS  PubMed  Google Scholar 

  13. Bestetti RB, Muccillo G (1997) Clinical course of Chagas’ heart disease: a comparison with dilated cardiomyopathy. Int J Cardiol 60:187–193

    Article  CAS  PubMed  Google Scholar 

  14. Blum JA, Zellweger MJ, Burri C, Hatz C (2008) Cardiac involvement in African and American trypanosomiasis. Lancet Infect Dis 8(10):631–641

    Article  PubMed  Google Scholar 

  15. Bocchi EA, Fiorelli A. First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology (2001) The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. Ann Thorac Surg 71:1833–1838

    Article  Google Scholar 

  16. Botoni FA, Poole-Wilson PA, Ribeiro AL, Okonko DO, Oliveira BM, Pinto AS, Teixeira MM, Teixeira AL Jr, Reis AM, Dantas JB, Ferreira CS, Tavares WC Jr, Rocha MO (2007) A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am Heart J 153(4):544. e1–544. e8

    Article  Google Scholar 

  17. Burki T (2011) Production of drugs for Chagas disease predicted to fall short. Lancet Infect Dis 11(12):901–902

    Article  Google Scholar 

  18. Carod-Artal FJ, Ribeiro LS, Vargas AP (2007) Awareness of stroke risk in chagasic stroke patients. J Neurol Sci 263:35–39

    Article  PubMed  Google Scholar 

  19. Chagas C (1909) Über eine neue Trypanosomiasis des Menschen. Archiv für Schiffs- und Tropen-Hygiene, Leipzig 13:351–353

    Google Scholar 

  20. Chagas C (1909) Neue Trypanosomen: vorläufige Mitteilung. Archiv für Schiffs- und Tropen-Hygiene, Leipzig 13:120–122

    Google Scholar 

  21. Cortez J, Providência R, Ramos E, Valente C, Seixas J, Meruje M, Leitão-Marques A, Vieira A (2012) Emerging and under-recognized Chagas cardiomyopathy in non-endemic countries. World J Cardiol 4(7):234–239

    Article  PubMed Central  PubMed  Google Scholar 

  22. Dávila DF, Angel F, Arata de Bellabarba G, Donis JH (2002) Effects of metoprolol in chagasic patients with severe congestive heart failure. Int J Cardiol 85:255–260

    Article  PubMed  Google Scholar 

  23. Di Girolamo C, Bodini C, Marta BL, Ciannameo A, Cacciatore F. (2011) Chagas disease at the crossroad of international migration and public health policies: why a national screening might not be enough. Euro Surveill 16(37):pii = 19965

    Google Scholar 

  24. Diniz RVZ (2004) Effect and tolerability of the carvediol in chronic symptomatic chagasic cardiomyopathy. Universidade Federal de São Paulo, São Paulo

    Google Scholar 

  25. Espinosa R, Carrasco HA, Belandria F, Fuenmayor AM, Molina C, González R, Martínez O (1985) Life expectancy analysis in patients with Chagas’ disease: prognosis after one decade (1973–1983). Int J Cardiol 8(1):45–56

    Article  CAS  PubMed  Google Scholar 

  26. Eurostat population by 1st of January. Available from: http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&init=1&language=de&pcode=tps00001&plugin=1

  27. Eurostat. Immigration by sex, age group and citizenship. Last update: 12 July 2012. Available from: http://epp.eurostat.ec.europa.eu/portal/page/portal/population/data/database

  28. Flores-Chavez MD, Merino FJ, García-Bujalance S, Martin-Rabadán P, Merino P, García-Bermejo I, Delgado A, Cuadros J, Working Group on Chagas Disease of Autonomous Community of Madrid. (2011) Surveillance of Chagas disease in pregnant women in Madrid, Spain, from 2008 to 2010. Euro Surveill 16(38):pii = 19974

    Google Scholar 

  29. Gascon J, Bern C, Pinazo MJ (2010) Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop 115(1–2):22–27

    Article  PubMed  Google Scholar 

  30. Guerri-Guttenberg RA, Grana DR, Ambrosio G, Milei J (2008) Chagas cardiomyopathy: Europe is not spared! Eur Heart J 29(21):2587–2591

    Article  PubMed  Google Scholar 

  31. Hidalgo R, Martí-Carvajal AJ, Kwong JS, Simancas-Racines D, Nicola S (2012) Pharmacological interventions for treating heart failure in patients with chagas cardiomyopathy. Cochrane Database Syst Rev 11:CD009077

    PubMed  Google Scholar 

  32. Higuchi Mde L, Benvenuti LA, Martins Reis M, Metzger M (2003) Pathophysiology of the heart in Chagas’ disease: current status and new developments. Cardiovasc Res 60(1):96–107

    Article  PubMed  Google Scholar 

  33. Jackson Y, Gétaz L, Wolff H, Holst M, Mauris A, Tardin A, Sztajzel J, Besse V, Loutan L, Gaspoz JM, Jannin J, Albajar Vinas P, Luquetti A, Chappuis F (2010) Prevalence, clinical staging and risk for blood-borne transmission of Chagas disease among Latin American migrants in Geneva, Switzerland. PLoS Negl Trop Dis 4(2):e592

    Article  PubMed Central  PubMed  Google Scholar 

  34. Kitchen AD, Hewitt PE, Chiodini PL (2012) The early implementation of Trypanosoma cruzi antibody screening of donors and donations within England: preempting a problem. Transfusion 52(9):1931–1939

    Article  PubMed  Google Scholar 

  35. Kropf SP, Sá MR (2009) The discovery of Trypanosoma cruzi and Chagas disease (1908–1909): tropical medicine in Brazil. Hist Cienc Saude Manguinhos 16(Suppl 1):13–34

    PubMed  Google Scholar 

  36. Lescure FX, Canestri A, Melliez H, Jauréguiberry S, Develoux M, Dorent R, Guiard-Schmid JB, Bonnard P, Ajana F, Rolla V, Carlier Y, Gay F, Elghouzzi MH, Danis M, Pialoux G (2008) Chagas disease, France. Emerg Infect Dis 14(4):644–646

    Article  PubMed  Google Scholar 

  37. Machado FS, Jelicks LA, Kirchhoff LV, Shirani J, Nagajyothi F, Mukherjee S, Nelson R, Coyle CM, Spray DC, de Carvalho AC, Guan F, Prado CM, Lisanti MP, Weiss LM, Montgomery SP, Tanowitz HB (2012) Chagas heart disease: report on recent developments. Cardiol Rev 20(2):53–65

    PubMed Central  PubMed  Google Scholar 

  38. Marin-Neto JA, Andrade ZA (1991) Why is there predominance of right heart failure in Chagas’ disease? Arq Bras Cardiol 57:181–183

    CAS  PubMed  Google Scholar 

  39. Marin-Neto JA, Rassi A Jr, Avezum A Jr, Mattos AC, Rassi A, Morillo CA, Sosa-Estani S, Yusuf S, BENEFIT Investigators (2009) The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz 104(Suppl 1):319–324 Erratum in: Mem Inst Oswaldo Cruz 104(6):937

    Article  CAS  PubMed  Google Scholar 

  40. Matsuda NM, Oliveira RB, Dantas RO, Iazigi N (1995) Effect of isosorbide dinitrate on gastroesophageal reflux in healthy volunteers and patients with Chagas’ disease. Dig Dis Sci 40(1):177–182

    Article  CAS  PubMed  Google Scholar 

  41. Medecins sans frontiers (2011) The Shortage of Benznidazole Leaves Thousands of Chagas Patients without Treatment. Briefing Document, October 2011

  42. Molina J, Martins-Filho O, Brener Z, Romanha AJ, Loebenberg D, Urbina JA (2000) Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother 44(1):150–155

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Muratore CA, Batista Sa LA, Chiale PA, Eloy R, Tentori MC, Escudero J, Lima AM, Medina LE, Garillo R, Maloney J (2009) Implantable cardioverter defibrillators and Chagas’ disease: results of the ICD Registry Latin America. Europace 11:164–168

    Article  PubMed  Google Scholar 

  44. Navarro M, Navaza B, Guionnet A, López-Vélez R (2012) Chagas disease in Spain: need for further public health measures. PLoS Negl Trop Dis 6(12):e1962

    Article  PubMed Central  PubMed  Google Scholar 

  45. Navarro M, Perez-Ayala A, Guionnet A, Perez-Molina JA, Navaza B, Estévez L, Norman F, Flores-Chávez M, Lopez-Velez R. (2011) Targeted screening and health education for Chagas disease tailored to at-risk migrants in Spain, 2007 to 2010. Euro Surveill. 16(38):pii = 19973

  46. Niemann M, Breunig F, Beer M, Herrmann S, Strotmann J, Hu K, Emmert A, Voelker W, Ertl G, Wanner C, Weidemann F (2010) The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy. Heart 96(23):1915–1919

    Article  CAS  PubMed  Google Scholar 

  47. Pan American Health Organization (PAHO). Estimación cuantitativa de la enfermedad de Chagas en las Américas. Quantitative estimation of Chagas disease in the Americas. Montevideo: PAHO; 2006. Report No.: OPS/HDM/CD/425-06

  48. Parada H, Carrasco HA, Anez N, Fuenmayor C, Inglessis I (1997) Cardiac involvement is a constant finding in acute Chagas’ disease: a clinical, parasitological and histopathological study. Int J Cardiol 60:49–54

    Article  CAS  PubMed  Google Scholar 

  49. Paricio-Talayero JM, Benlloch-Muncharaz MJ, Collar-del-Castillo JI, Rubio-Soriano A, Serrat-Perez C, Magraner-Egea J, Landa-Rivera L, Sánchez-Palomares M, Beseler-Soto B, Santos-Serrano L, Ferriol-Camacho M, Mut-Buigues J, Tomás-Vila M, del Carmen Alonso-Jiménez M, Domínguez-Márquez V, Igual-Adell R (2008) Vigilancia epidemiológica de la transmisión vertical de la enfermedad de Chagas en tres maternidades de la Comunidad Valenciana. Enferm Infecc Microbiol Clin 26(10):609–613

    Article  PubMed  Google Scholar 

  50. Pereira BI, Nazareth C, Malcata L, Alves H, Fernandez JR, Sargento C, da Cunha S (2011) Transfusion-transmitted protozoal infections: what is the risk in non-endemic countries? Acta Med Port 24:897–906

    PubMed  Google Scholar 

  51. de Pérez Pedro I, Martín Rico P, Santamaría S, Faez Y, Blanc P, Pascual MªJ, Cuesta MªA, Villalta MªC, Muñoz Pérez MI, Vidales I, Heiniger AI (2008) Caso clínico de Chagas transfusional. Emf Emerg 10(Supl 1):14–18

    Google Scholar 

  52. Pérez-López FR, Chedraui P (2010) Chagas disease in pregnancy: a non-endemic problem in a globalized world. Ach Gynecol Obstet 282:595–599

    Article  Google Scholar 

  53. Pinazo MJ, Espinosa G, Gállego M, López-Chejade PL, Urbina JA, Gascón J (2010) Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg 82(4):583–587

    Article  CAS  PubMed  Google Scholar 

  54. Rassi A Jr, Dias JC, Marin-Neto JA, Rassi A (2009) Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas’ disease. Heart 95(7):524–534

    Article  CAS  PubMed  Google Scholar 

  55. Rassi A Jr, Rassi A, Marin-Neto JA (2009) Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification. Mem Inst Oswaldo Cruz 104(Suppl. I):152–158

    Article  PubMed  Google Scholar 

  56. Rassi A Jr, Rassi A, Marin-Neto JA (2010) Chagas disease. Lancet 375(9723):1388–1402

    Article  PubMed  Google Scholar 

  57. Rassi A Jr, Rassi A, Rassi SG (2007) Predictors of mortality in chronic Chagas’ disease. Circulation 115:1101–1108

    Article  PubMed  Google Scholar 

  58. Rassi A, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, Rassi GG, Hasslocher-Moreno A, Sousa AS, Scanavacca MI (2006) Development and validation of a risk score for predicting mortality in Chagas’ heart disease. N Engl J Med 355:799–808

    Article  CAS  PubMed  Google Scholar 

  59. Rassi A Jr, Rassi A, Rassi SG (2007) Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation 115:1101–1108

    Article  PubMed  Google Scholar 

  60. Roca C, Pinazo MJ, López-Chejade P, Bayó J, Posada E, López-Solana J, Gállego M, Portús M, Gascón J, Chagas-Clot Research Group (2011) Chagas disease among the Latin American Adult Population Attending in a Primary Care Center in Barcelona, Spain. PLoS Negl Trop Dis 5(4):e1135

    Article  PubMed Central  PubMed  Google Scholar 

  61. Sandahl K, Botero-Kleiven S, Hellgren U (2011) Chagas’ disease in Sweden: great need of guidelines for testing. Probably hundreds of seropositive cases, only a few known. Lakartidningen 108(46):2368–2371

    PubMed  Google Scholar 

  62. Schmunis GA (1991) Trypanosoma cruzi, the etiologic agent of Chagas disease: status in the blood supply in endemic and non endemic countries. Transfusion 31:547–557

    Article  CAS  PubMed  Google Scholar 

  63. Schmunis GA, Yadon ZE (2010) Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop 115(1–2):14–21

    Article  PubMed  Google Scholar 

  64. Schmunis GA (2007) Epidemiology of Chagas disease in non endemic countries: the role of international migration. Mem Inst Oswaldo Cruz 102(suppl 1):75–85

    Article  PubMed  Google Scholar 

  65. Silva JJ, Pavanelli WR, Pereira JC, Silva JS, Franco DW (2009) Experimental chemotherapy against Trypanosoma cruzi infection using ruthenium nitric oxide donors. Antimicrob Agents Chemother 53(10):4414–4421

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  66. Tanowitz HB, Kirchhoff LV, Simon D, Morris SA, Weiss LM, Wittner M (1992) Chagas’ disease. Clin Microbiol Rev 5(4):400–419

    CAS  PubMed Central  PubMed  Google Scholar 

  67. Tura BR, Martino HF, Gowdak LH, Ribeiro dos Santos R, Dohmann HF, Krieger JE, Feitosa G, Vilas-Boas F, Oliveira SA, Silva SA, Bozza AZ, Borojevic R, Campos de Carvalho AC (2007) Multi-center randomized trial of cell therapy in cardiopathies: MiHeart Study. Trials 8:2

    Article  PubMed Central  PubMed  Google Scholar 

  68. Vespa GN, Cunha FQ, Silva JS (1994) Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro. Infect Immun 62(11):5177–5182

    CAS  PubMed Central  PubMed  Google Scholar 

  69. Wendel S (1998) Transfusion: transmitted Chagas’ disease. Curr Opin Hematol 5:406–411

    Article  CAS  PubMed  Google Scholar 

  70. World Health Organization (WHO) (2012) Chagas disease (American trypanosomiasis): fact sheet (revised in August 2012). Wkly Epidemiol Rec 87(51/52):519–522

    Google Scholar 

  71. World Health Organization (WHO) (1991) Control of Chagas disease. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 811:1–95

    Google Scholar 

  72. World Health Organization (WHO). Control and prevention of Chagas disease in Europe. Report of a WHO Informal Consultation (jointly organized by WHO headquarters and the WHO Regional Office for Europe) Geneva, Switzerland,17–18 December 2009. Geneva: WHO; 2010. Report No: WHO/HTM/NTD/IDM/2010.1

  73. Zoller T, Wirth M, Stich A. (2013) http://www.chagas.info

Download references

Acknowledgements

J.S. is supported by the Else-Kröner-Forschungskolleg Würzburg. The authors thank Dr. Tilman Schenk for his assistance generating Figure 1.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Cardiology, Clinic for Internal Medicine I, University Hospital Würzburg, Würzburg, Germany

    Jörn Strasen, Tatjana Williams, Georg Ertl & Oliver Ritter

  2. Department of Pneumology and Infectiology, Charité Berlin, Berlin, Germany

    Thomas Zoller

  3. Department of Tropical Medicine, Missionsärztliche Klinik Würzburg, Würzburg, Germany

    August Stich

  4. Comprehensive Heart Failure Center Würzburg, Würzburg, Germany

    Georg Ertl & Oliver Ritter

Authors
  1. Jörn Strasen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tatjana Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Georg Ertl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas Zoller
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. August Stich
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Oliver Ritter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jörn Strasen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Strasen, J., Williams, T., Ertl, G. et al. Epidemiology of Chagas disease in Europe: many calculations, little knowledge. Clin Res Cardiol 103, 1–10 (2014). https://doi.org/10.1007/s00392-013-0613-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-013-0613-y

Keywords

Search

Navigation